Publication: Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network.
Loading...
Identifiers
Date
2020
Authors
Bukkems, Vera
Necsoi, Coca
Tenorio, Carmen Hidalgo
Garcia, Coral
Rockstroh, Jürgen
Schwarze-Zander, Caroline
Lambert, John S
Burger, David
Konopnicki, Deborah
Colbers, Angela
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
This phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir concentration at the end of the dosing interval (Ctrough) was reduced by 77%, with 85% of pregnant women having a Ctrough below the effective concentration (EC90). Clinical Trials Registration. NCT00825929.
Description
MeSH Terms
Anti-HIV Agents
Anti-Retroviral Agents
Female
HIV Infections
Humans
Pregnancy
Pregnancy Complications, Infectious
Pregnancy Trimester, Third
Pregnant Women
Quinolones
Anti-Retroviral Agents
Female
HIV Infections
Humans
Pregnancy
Pregnancy Complications, Infectious
Pregnancy Trimester, Third
Pregnant Women
Quinolones
DeCS Terms
CIE Terms
Keywords
HIV, cobicistat, elvitegravir, pharmacokinetics, pregnancy